{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Laboratory+Assessments",
    "query": {
      "intervention": "Laboratory Assessments"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1797,
    "total_pages": 180,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Laboratory+Assessments&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T15:55:17.255Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02048813",
      "title": "Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacogenomic Study",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 529,
      "start_date": "2014-03-10",
      "completion_date": "2026-10-09",
      "has_results": true,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-02T15:55:17.255Z",
      "location_count": 781,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 509 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02048813"
    },
    {
      "nct_id": "NCT02454517",
      "title": "Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Adenocarcinoma",
        "Stage I Prostate Cancer AJCC V7",
        "Stage IIA Prostate Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Behavioral Dietary Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Exercise Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Informational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "40 Years and older · Male only"
      },
      "enrollment_count": 117,
      "start_date": "2016-05-19",
      "completion_date": "2021-09-30",
      "has_results": true,
      "last_update_posted_date": "2023-01-04",
      "last_synced_at": "2026-09-02T15:55:17.255Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02454517"
    },
    {
      "nct_id": "NCT02339740",
      "title": "Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA"
      ],
      "interventions": [
        {
          "name": "Arsenic Trioxide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mitoxantrone Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Tretinoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 158,
      "start_date": "2015-07-21",
      "completion_date": "2029-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-09-02T15:55:17.255Z",
      "location_count": 152,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02339740"
    },
    {
      "nct_id": "NCT05918185",
      "title": "Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Comprehensive Geriatric Assessment",
          "type": "OTHER"
        },
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2023-02-15",
      "completion_date": "2025-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-09-02T15:55:17.255Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05918185"
    },
    {
      "nct_id": "NCT04729959",
      "title": "Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Astrocytoma, IDH-Wildtype",
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Fractionated Stereotactic Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Tocilizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2022-03-11",
      "completion_date": "2026-09-04",
      "has_results": true,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-09-02T15:55:17.255Z",
      "location_count": 110,
      "location_summary": "Anaheim, California • Bellflower, California • Los Angeles, California + 89 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04729959"
    },
    {
      "nct_id": "NCT03701282",
      "title": "Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 720,
      "start_date": "2019-02-12",
      "completion_date": "2028-05-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-02T15:55:17.255Z",
      "location_count": 864,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 552 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03701282"
    },
    {
      "nct_id": "NCT06369220",
      "title": "A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chlamydia Trachomatis Infection",
        "Neisseria Gonorrhoeae Infection",
        "Mycoplasma Genitalium Infection"
      ],
      "interventions": [
        {
          "name": "cobas® liat CT/NG/MG nucleic acid test",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Standard of Care (SOC): Clinician's Standard Practice",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 331,
      "start_date": "2024-07-29",
      "completion_date": "2025-05-28",
      "has_results": true,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-09-02T15:55:17.255Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Hamilton Square, New Jersey • Perth Amboy, New Jersey + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Hamilton Square",
          "state": "New Jersey"
        },
        {
          "city": "Perth Amboy",
          "state": "New Jersey"
        },
        {
          "city": "Killeen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06369220"
    },
    {
      "nct_id": "NCT04048018",
      "title": "Performance Evaluation of the VIDAS TB-IGRA Assay.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Active Tuberculosis",
        "Latent Tuberculosis Infection",
        "Non-Tuberculous Mycobacterial (NTM) Pneumonia"
      ],
      "interventions": [
        {
          "name": "Blood draw and IGRA test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "BioMérieux",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 2401,
      "start_date": "2019-12-05",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-07-16",
      "last_synced_at": "2026-09-02T15:55:17.255Z",
      "location_count": 7,
      "location_summary": "Palo Alto, California • San Diego, California • Denver, Colorado + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04048018"
    },
    {
      "nct_id": "NCT05437679",
      "title": "Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "High Risk Prostate Carcinoma",
        "Biochemically Recurrent Prostate Carcinoma",
        "Castration-resistant Prostate Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Blood collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Angle plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2022-07-05",
      "completion_date": "2023-08-22",
      "has_results": false,
      "last_update_posted_date": "2023-09-05",
      "last_synced_at": "2026-09-02T15:55:17.255Z",
      "location_count": 2,
      "location_summary": "Bala-Cynwyd, Pennsylvania • Pottstown, Pennsylvania",
      "locations": [
        {
          "city": "Bala-Cynwyd",
          "state": "Pennsylvania"
        },
        {
          "city": "Pottstown",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05437679"
    },
    {
      "nct_id": "NCT01456013",
      "title": "Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Contrast Induced Nephropathy"
      ],
      "interventions": [
        {
          "name": "RenalGuard Therapy",
          "type": "DEVICE"
        },
        {
          "name": "Standard Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "CardioRenal Systems, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 326,
      "start_date": "2012-01",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2023-02-16",
      "last_synced_at": "2026-09-02T15:55:17.255Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Torrance, California • Washington D.C., District of Columbia + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01456013"
    }
  ]
}